Sarcoma Clinical Trials
Patients with sarcoma can consider clinical trials to expand their range of treatment options. In a clinical trial, researchers provide one group of patients with an investigational therapy, such as a novel chemotherapy drug, while providing a second group of patients with the best treatment that is currently available. This helps patients access the newest treatments before they are offered to the public, while helping researchers determine which treatments produce the best outcomes and the fewest side effects.
The Only Florida-based NCI-designated Comprehensive Cancer Center
Recognized for its scientific excellence, Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.
Recent sarcoma clinical trials have investigated treatments such as:
- New medications for chemotherapy-resistant sarcomas
- New drug combinations for sarcomas that cannot be surgically removed
- Proton therapy as an alternative to X-ray-based radiation therapy
- Peripheral stem cell transplantation as a potential sarcoma treatment
- Antibody-based treatments for recurrent sarcomas
- Less toxic treatments for pediatric sarcoma patients
Other sarcoma clinical trials have explored risk factors, screening methods, preventive options and techniques to improve the likelihood of early diagnosis. For instance, researchers have linked several genetic syndromes to an increased risk of developing sarcoma, and this information has led to better awareness for these individuals. Through clinical trials, researchers are improving options not just for current patients, but for every individual who will face a sarcoma diagnosis in the future.
As part of our commitment to ongoing research, Moffitt Cancer Center offers an extensive range of clinical trials, with options for patients with many different types and stages of sarcoma. These trials are overseen by our expert oncologists and research professionals; careful monitoring ensures that every participant receives the best possible treatment for his or her needs. In recognition of our extensive research efforts, the National Cancer Institute awarded Moffitt Cancer Center with its prestigious Comprehensive Cancer Center designation.
For more information about sarcoma clinical trials, or to enroll in one of Moffitt Cancer Center’s ongoing trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Referrals are not required to seek treatment at Moffitt and participate in our clinical trials.
Helpful Links:
-
Clinical Trials
CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()
CLINICAL TRIAL 22695
ADI-PEG 20 (Pegargiminase) or Placebo (PBO) plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
Condition: Sarcoma
Intervention: ADI-PEG 20 (); Gemzar (gemcitabine); Placebo (); Taxotere (docetaxel); docetaxel (); gemcitabine ()
CLINICAL TRIAL 23281
Metastatic Ewing s Trial Testing Schedule Enhancement to Improve Outcomes
Condition: Sarcoma
Intervention: Actinomycin D (Dactinomycin); Adriamycin (doxorubicin); CPT-11 (irinotecan); Cabozantinib (XL 184); Camptosar (irinotecan); Dactinomycin (); Doxil (doxorubicin liposome); Etoposide (); Ifosfamide (); Radiotherapy (); Topotecan (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); doxorubicin liposome (); irinotecan ()
CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()
CLINICAL TRIAL 23609
Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); PM01183 (lurbinectedin); doxorubicin (); lurbinectedin ()
CLINICAL TRIAL 24010
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); Pembrolizumab (Keytruda); doxorubicin ()